AstraZeneca PLC American Depositary Shares (AZN)
NASDAQ (NGS) NASDAQ (NGS) Primary 
AstraZeneca: Q4 Earnings Analysis - Ticks The Boxes, Upgrading To Buy
AstraZeneca PLC delivered robust 2025 results, with 9% product sales growth and a 23.4% operating margin, and raised its dividend. AZN targets $80bn in revenues by 2030, driven by oncology, pipeline launches, and a $50bn US investment; management expresses increasing confidence. Patent expirations loom for key drugs, but pipeline assets and AI-driven innovation are expected to offset risks and sustain growth.
AstraZeneca PLC (AZN) Q4 2025 Earnings Call Transcript
AstraZeneca PLC (AZN) Q4 2025 Earnings Call Transcript
AZN Q4 Earnings Miss Estimates, Stock Up on Robust 2026 Growth Outlook
AZN misses Q4 EPS and sales estimates, but rallies after projecting mid-to-high single-digit revenue growth and low double-digit EPS growth for 2026.
Here's What Key Metrics Tell Us About Astrazeneca (AZN) Q4 Earnings
The headline numbers for Astrazeneca (AZN) give insight into how the company performed in the quarter ended December 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
AstraZeneca's growth engine stays on track despite cost pressures
AstraZeneca PLC's (LSE:AZN, NASDAQ:AZN) full-year results showed the pharmaceutical group navigating a challenging comparison period with a robust operational performance and a renewed commitment to long-term growth, analysts said. Fourth-quarter revenue came in at $15.5 billion, 2% ahead at constant exchange rates and just over 1% above consensus.
AstraZeneca lifts earnings as pipeline delivery and global expansion underpin growth
AstraZeneca PLC (LSE:AZN, NASDAQ:AZN) delivered strong full-year results for 2025, driven by solid commercial performance across all major regions and sustained pipeline momentum, as the Anglo-Swedish pharmaceutical group continued what it called a “catalyst-rich period.” Total revenue for the year rose 8% at constant exchange rates to $58.7 billion, with product sales contributing $55.6 billion, up 9%.
AstraZeneca profit climbs on cancer and heart drug demand
The pharmaceutical giant announced profit in line with expectations and revenue that slightly beat forecasts on Tuesday.
Drugmaker AstraZeneca forecasts sales and profit growth in 2026
AstraZeneca on Tuesday forecast profit and sales growth in 2026, betting on demand for its cancer and cardiovascular treatments while the drugmaker pursues massive expansion in the U.S. and China.
Will These 5 Drug Bigwigs Surpass Q4 Earnings Forecasts?
Let's look at five pharma and biotech companies, AZN, INCY, GILD, VRTX and MRNA, which are scheduled to release their fourth-quarter 2025 results this week.
Countdown to Astrazeneca (AZN) Q4 Earnings: A Look at Estimates Beyond Revenue and EPS
Besides Wall Street's top-and-bottom-line estimates for Astrazeneca (AZN), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended December 2025.
AstraZeneca to Report Q4 Earnings: What's in Store for the Stock?
AZN gears up for Q4 results as cancer, diabetes and rare disease drugs drive sales expectations ahead of the Feb. 10 earnings report.
FDA Rejects AZN's Saphnelo SubQ Formulation, Priority Tag to Datroway
AstraZeneca wins FDA priority review for Datroway in triple-negative breast cancer, while Saphnelo SC receives a complete response letter.
